In last trading session, Harvard Bioscience Inc (NASDAQ:HBIO) saw 0.39 million shares changing hands with its beta currently measuring 1.27. Company’s recent per share price level of $1.90 trading at -$0.25 or -11.63% at ring of the bell on the day assigns it a market valuation of $82.88M. That closing price of HBIO’s stock is at a discount of -162.63% from its 52-week high price of $4.99 and is indicating a discount of -2.63% from its 52-week low price of $1.95. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.17 million shares which gives us an average trading volume of 163.14K if we extend that period to 3-months.

For Harvard Bioscience Inc (HBIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.05 in the current quarter.

Harvard Bioscience Inc (NASDAQ:HBIO) trade information

Upright in the red during last session for losing -11.63%, in the last five days HBIO remained trading in the red while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $1.90 price level, adding 16.67% to its value on the day. Harvard Bioscience Inc’s shares saw a change of -9.95% in year-to-date performance and have moved -6.40% in past 5-day. Harvard Bioscience Inc (NASDAQ:HBIO) showed a performance of -18.45% in past 30-days. Number of shares sold short was 0.53 million shares which calculate 2.96 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 72.86% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -268.42% in reaching the projected high whereas dropping to the targeted low would mean a loss of -268.42% for stock’s current value.

Harvard Bioscience Inc (HBIO) estimates and forecasts

This year revenue growth is estimated to fall -16.48% from the last financial year’s standing.

2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 24.15M for the same. And 2 analysts are in estimates of company making revenue of 22.95M in the next quarter. Company posted 28.15M and 24.51M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.80% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -67.86% while estimates for its earnings growth in next 5 years are of 10.00%.

Harvard Bioscience Inc (NASDAQ:HBIO)’s Major holders

Insiders are in possession of 7.22% of company’s total shares while institution are holding 75.99 percent of that, with stock having share float percentage of 81.91%. Investors also watch the number of corporate investors in a company very closely, which is 75.99% institutions for Harvard Bioscience Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HBIO for having 2.84 million shares of worth $8.1 million. And as of 2024-06-30, it was holding 6.5519 of the company’s outstanding shares.

The second largest institutional holder is PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC., which was holding about 2.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3876 of outstanding shares, having a total worth of $7.9 million.

On the other hand, Vanguard Total Stock Market Index Fund and Heartland Value Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.26 shares of worth $2.4 million or 2.89% of the total outstanding shares. The later fund manager was in possession of 1.2 shares on Sep 30, 2024 , making its stake of worth around $2.28 million in the company or a holder of 2.75% of company’s stock.